99% Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors Get link Facebook X Pinterest Email Other Apps BusinessWire Get link Facebook X Pinterest Email Other Apps